Find disease awareness content and relevant supporting materials
Genetics, diagnosis and clinical features of congenital hypodysfibrinogenemia: a systematic literature review and report of a novel mutation.
Background: Hypodysfibrinogenemia is a rare disease characterized by decreased levels of a dysfunctional fibrinogen. It shares features with both hypo? and dysfibrinogenemia, although with specific molecular patterns and...
Levetiracetam Seacross 100 mg/ml concentrate for solution for infusion
Levetiracetam Seacross is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. Levetiracetam Seacross is indicated as adjunctive therapy • in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. • in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy. Levetiracetam Seacross concentrate is an alternative for patients when oral administration is temporarily not feasible.
VTEval Project - A Prospective Cohort Study to Evaluate Diagnosis, Management and Outcome in Individuals With Venous Thromboembolism
Venous thromboembolism (VTE) with its two clinical manifestations deep vein thrombosis (DVT) and pulmonary embolism (PE) is a life-threatening disease...